Clinical and economical analysis of efficacy of levofloxacin (Tavanic) in patients with community-acquired pneumonia
Abstract
This study was devoted to comparative clinical-and-economical analysis of levofloxacin and ceftriaxone/cefuroxime axetyl for treatment of community-acquired pneumonia. The study was based on results of the opened multi-center comparative randomized clinical trial of T.M.File, J.Sergeti, R. Player et al. (1997) which had demonstrated a statistically significant difference in the antibiotic effectiveness at the 5th to 7th days of the therapy. A sensitivity of the model to the cost range and to a potential rate variability of different administering of the drugs was also investigated.
The final analysis of the antibiotics efficacy involved 226 patients treated with levofloxacin and 230 ones received ceftriaxone/cefuroxime axetyl. The therapy was clinically sufficient to the 5th-7th day in 96% of the patients treated with levofloxacin and 90% patients received ceftriaxone/cefuroxime axetyl (the 95% confidence interval was 10.7 to 1.3%). According to our results Tavanic was more benefit compared with the Rocephin/Zinnat mode as it was more effective and less expensive.
The conclusive results regarding the economic benefit of levofloxacin requires further clinical and economical trials to compare levofloxacin with other domestic modes for the therapy of the community-acquired pneumonia.
About the Authors
P. A. Vorobiev
МОО "Общество фармакоэкономических исследований"
Russian Federation
Russian Federation
I. B. Gorbunova
МОО "Общество фармакоэкономических исследований"
Russian Federation
Russian Federation
M. V. Avksentieva
МОО "Общество фармакоэкономических исследований"
Russian Federation
Russian Federation
References
1. Антибактериальная терапия пневмоний у взрослых: Учеб.- метод. пособие для врачей / Навашин С.М., Чучалин А.Г., Белоусов Ю.Б. и др. М.; 1998.
2. Синопальников А.И., Дуганов В.К. Левофлоксацин: ступенчатая терапия внебольничной пневмонии у взрослых. Рус. мед. журн. 2001; 15: 3-10.
3. Стандарты (протоколы) диагностики и лечения больных с неспецифическими заболеваниями легких (Приложение к приказу № 300 Минздрава России). М.; Универсум Паблишинг; 1999.
4. Чучалин А.Г. Болезни органов дыхания. Мед. газета 2000; 43: 8-9.
5. Bartlett J.G., Breiman R.F., Mandell L.A., File Т.М. Community-acquired pneumonia in adults: guidelines lor management. Infectious Diseases Society of America. Clin. Infect. Dis. 1998; 26: 811-838.
6. Bartlett J.G., Dowell S.F., Mandell L.A. et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Ibid. 2000; 31: 347-382.
7. File T.M., Sergeti J., Player R. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41: 1965-1972.
8. Mandell L.A., Marrie T.J., Grossman R.F. et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin. Infect. Dis. 2000; 31: 383-421.
9. Niederman M .S., Bass J.B., Campbell A.M. et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy: American Thoracic Society, Medical Section of the American Lung Association. Am. Rev. Respir. Dis. 1993; 148: 1418-1426.
Review
For citations:
Vorobiev P.A., Gorbunova I.B., Avksentieva M.V. Clinical and economical analysis of efficacy of levofloxacin (Tavanic) in patients with community-acquired pneumonia. PULMONOLOGIYA. 2003;(1):67-71. (In Russ.)
Views:
626
Email this article 